David S. Moore
Independent DirectorMr. David S. Moore, also known as Dave, is Independent Director of Corvus Pharmaceuticals, Inc. from October 2, 2025. He serves as Director at Naveris Inc. He served as the President of Cempra, Inc. from December 09, 2016 to May 5, 2017 and as its Chief Commercial Officer from January 07, 2014 to May 5, 2017. Mr. Moore served as an Executive Vice President of Cempra, Inc. since January 07, 2014. Mr. Moore served as the Chief Business Officer of Ocera Therapeutics, Inc. from January 15, 2013 to December 5, 2013 and served as its Vice President of Commercial Operations from August 2011 to January 2013. He served as the Chief Business Officer of Tranzyme, Inc. He served as Chief Business Officer at Tranzyme Pharma, Inc. since January 15, 2013. Mr. Moore was Executive VP of Corporate Development from March 07, 2023 to 2025. Mr. Moore was Executive VP of US Operations of Novo Nordisk A/S from January 1, 2025 until February 2026 and was its Member of Management Board since March 7, 2023 until February 2026 and served as its Executive VP of Global Business Development since January 1, 2025 until April 2025 and joined the Novo Nordisk A/S in 2017 and rejoined the company in September 2022 and was senior vice president for Corporate Development since September 2022 and in March 2023 he was promoted to executive vice president for Corporate Development until January 1, 2025. From 2019 to 2022 Mr Moore first served as CEO of the infectious disease business at Roivant Sciences, followed by being investment partner with Gurnet Point. Mr. Moore served as Vice President of Commercial Operations at Tranzyme, Inc. since August 2011. He served as Vice President of Commercial Operations at Tranzyme Pharma, Inc. since August 2011. He has spent over 15 years developing and managing pharmaceutical commercial programs, with the majority of those years spent with the Ortho-McNeil and Janssen Pharmaceutical divisions within Johnson & Johnson. He has held leadership roles in key sales and marketing functions and was part of teams that developed and executed launch plans for several prescription pharmaceuticals for both primary and acute care settings. Mr. Moore was also responsible for developing payer value platforms for several therapeutic areas including antibiotics, pain and women's health, in which he successfully implemented pricing and reimbursement strategies with hospitals and managed care organizations. He began his pharmaceutical career with Ortho-McNeil Janssen Pharmaceuticals, a Member of the Johnson & Johnson Family of Companies, where he held positions of increasing responsibility, served as Group Director of pain franchise. He served as a Director of Sirona Biochem Corp. from January 23, 2014 to October 28, 2017. Mr. Moore received his B.S. in Biology from Towson University in 1997 and his MBA in marketing from Lehigh University in 2003 and completed Health Policy Graduate Program, Thomas Jefferson University, United States in 2011.
Positions
- Company NameCorvus Pharmaceuticals, Inc.Stock CodeCRVSPositionIndependent DirectorColleagues
- RARichard A. MillerCo-Founder, President, CEO & Chairman of the Board
- PAPeter A. ThompsonCo-Founder & Independent Director
- LLLeiv LeaChief Financial Officer
- WBWilliam Benton JonesSenior Vice President of Pharmaceutical Development
- ZKZack KubowVice President of Investor Relations & Corporate Communications
- RARichard A. van den BroekIndependent Director
- LSLinda S. GraisIndependent Director
